All In Biotech

Drug Trial Radar · NCT06695897

A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

Prospective, Non-interventional Observational Study to Characterize Dupilumab in the Long-term Management of Eosinophilic Esophagitis, Safety and Patient Reported Outcomes (Quality of Life) in Clinical Routine

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Jun 1, 2027

Study completion May 29, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with respect to their medical history, socio-demographic and disease characteristics, comorbidities (including type 2 inflammatory and atopic conditions), concomitant therapies and prior EoE treatments. Furthermore, this NIS aims to describe the long-term effectiveness of dupilumab for the treatment of EoE as assessed by the treating physician and reported by the patient, and its effect on health-related quality of life (HRQoL) during an individual observational period of two years. In addition, data on real-world use patterns and long-term safety data of dupilumab treatment for EoE will be collected.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • DupilumabDrug

    This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Descriptive statistical analysis of medical history characteristicsTime frame: At baseline
  2. Descriptive statistical analysis of socio-demographic characteristicsTime frame: At baseline
  3. Descriptive statistical analysis of disease characteristicsTime frame: At baseline

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number: 0000004

    Berlin, Germany · Recruiting

  • Investigational Site Number: 0000009

    Aschaffenburg, Bavaria, Germany · Recruiting

  • Investigational Site Number: 0000014

    Augsburg, Bavaria, Germany · Recruiting

  • Investigational Site Number: 0000001

    Dachau, Bavaria, Germany · Recruiting

  • Investigational Site Number: 0000012

    Erlangen, Bavaria, Germany · Recruiting

  • Investigational Site Number: 0000005

    Giessen, Hesse, Germany · Recruiting

  • Investigational Site Number: 0000011

    Wetzlar, Hesse, Germany · Recruiting

  • Investigational Site Number: 0000013

    Osnabrück, Lower Saxony, Germany · Recruiting

  • Investigational Site Number: 0000002

    Weyhe-Kirchweyhe, Lower Saxony, Germany · Recruiting

  • Investigational Site Number: 0000007

    Bochum, North Rhine-Westphalia, Germany · Recruiting

  • Investigational Site Number: 0000003

    Burbach, North Rhine-Westphalia, Germany · Recruiting

  • Investigational Site Number: 0000006

    Guelders, North Rhine-Westphalia, Germany · Recruiting

  • Investigational Site Number: 0000010

    Münster, North Rhine-Westphalia, Germany · Recruiting

  • Investigational Site Number: 0000008

    Leipzig, Saxony, Germany · Recruiting

  • Investigational Site Number: 0000015

    Magdeburg, Saxony-Anhalt, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.